Infinity Pharmaceuticals Financial Diagnostics

Infinity Pharmaceuticals -- USA Stock  

USD 2.24  0.04  1.82%

Infinity Pharmaceuticals diagnostics interface makes it easy to digest most current publicly released information about Infinity Pharmaceuticals as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analysis Infinity Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.
About 54.0% of the company shares are owned by institutional investors. The book value of Infinity Pharmaceuticals was currently reported as 0.94. The company recorded loss per share of 0.83. Infinity Pharmaceuticals had not issued any dividends in recent years. This company had 1:4 split on 2006-09-13. Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for patients with difficult-to-treat diseases in the United States. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts. Infinity Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ. It employs 22 people. To learn more about INFINITY PHARMACE call Adelene Perkins at 617-453-1000 or check out http://www.infi.com.

Infinity Pharmaceuticals Alerts

Infinity Pharmaceuticals appears to be very risky and stock price may revert if volatility continues
Infinity Pharmaceuticals has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company reported previous year revenue of 6 M. Net Loss for the year was (41.83 M) with profit before overhead, payroll, taxes, and interest of 6 M.
INFINITY PHARMACE currently holds about 57.61 M in cash with (36.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.11.

Infinity Pharmaceuticals Upcoming Events

Upcoming Quarterly ReportFebruary 28, 2017
Next Earnings ReportMay 3, 2017

Infinity Pharmaceuticals EPS Estimate

EPSEstimate Date
Quarterly Estimate-0.56February 28, 2017

Infinity Pharmaceuticals SEC Filings

Financial Statements and Exhibits. Other Events
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure. Results of Operations and Financial Condition
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Unclassified Corporate Event
Financial Statements and Exhibits. Results of Operations and Financial Condition

Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 115.87 M.

Management Efficiency

Infinity Pharmaceuticals has return on total asset (ROA) of (24.62) % which means that it has lost $24.62 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (64.26) % meaning that it created substantial loss on money invested by shareholders.

Stock Holders for Infinity Pharmaceuticals

Technical Drivers

Infinity Pharmaceuticals retains Downside Deviation of 5.9, Market Risk Adjusted Performance of 12.23 and Risk Adjusted Performance of 0.1639. Infinity Pharmaceuticals technical analysis makes it possible for you to employ historical prices and volume momentum with intention to determine a pattern that calculates the direction of the corporation future prices. In other words you can use this information to find out if the corporation will indeed mirror its model of historical price patterns or the prices will eventually revert. We found nineteen technical drivers for Infinity Pharmaceuticals which can be compared to its competitors. Please check out Infinity Pharmaceuticals Treynor Ratio, and the relationship between Standard Deviation and Downside Variance to decide if Infinity Pharmaceuticals is priced fairly providing market reflects its last-minute price of 2.24 per share. Please also validate Infinity Pharmaceuticals Total Risk Alpha which is currently at 1.03 to confirm the company can sustain itself at future point.

Infinity Pharmaceuticals Price Movement Analysis

Study
Time Period
Deviations up
Deviations down
MA Type
  Portfolio Suggestion    
  
Execute Study
 
The output start index for this execution was eleven with a total number of output elements of twenty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Infinity Pharmaceuticals middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Infinity Pharmaceuticals. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target. View also all equity analysis or get more info about bollinger bands overlap studies indicator.

Infinity Pharmaceuticals Insider Trading Activities

Infinity Pharmaceuticals Technical and Predictive Indicators

Infinity Pharmaceuticals Corporate Filings

Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations

Infinity Pharmaceuticals Forecast Models

Trending Equities

What people are investing to
F   
 NYQ 
Purchased over 200 shares of
few hours ago
Traded for 10.96
MSFT   
 NMS 
Purchased over 30 shares of
few hours ago
Traded for 96.11
GM   
 NYQ 
Purchased over 70 shares of
few hours ago
Traded for 37.77
DD   
 NYQ 
Purchased over 100 shares of
few hours ago
Traded for 30.6
CRM   
 NYQ 
Purchased over 20 shares of
few hours ago
Traded for 124.06
RKDA   
 NCM 
Purchased over 100 shares of
few hours ago
Traded for 23.82

Generate Optimal Portfolios

Align your risk and return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.